Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data-Reference-Cited by-同舟云学术

Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data

Published:2024-06 Issue:6 Volume:22 Page:1640-1648
ISSN:1538-7836
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:Journal of Thrombosis and Haemostasis

Author:

Cho Hyunjeong,Yoo Ki Young,Shin Ju-Young,Lee Eun-Kyoung,Choi BongKyoo

Funder

CHA University

Sookmyung Women's University

Publisher

Elsevier BV

Reference33 articles.

1. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A;Shima;N Engl J Med,2016

2. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity;Kitazawa;Int J Hematol,2020

3. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies;Callaghan;Blood,2021

4. Deaths associated with emicizumab in patients with hemophilia A;Aledort;N Engl J Med,2019

5. Emicizumab prophylaxis in haemophilia A with inhibitors: three years follow-up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO);Wall;Haemophilia,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.;Journal of Thrombosis and Haemostasis;2024-09

2. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders;Research and Practice in Thrombosis and Haemostasis;2024-05